Following a similar path, the CAR-targeting of a lymphoid/plasma cell-restricted surface antigen, B-cell maturation antigen (BCMA), has multiple myeloma on the precipice of at least one approved CAR T product. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.